Nanosonics Limited (ASX:NAN) Launches trophon3 and trophon2 Plus
Nanosonics Limited (ASX:NAN) launches trophon3 and trophon2 Plus, enhancing infection prevention with faster disinfection and advanced digital integration.
Category: Healthcare
Imugene Limited (ASX:IMU) Receives $5.8m R&D Tax Refund
Imugene Limited (ASX:IMU) receives a A$5.8m R&D tax refund to advance its immuno-oncology pipeline.
OncoSil Medical Limited (ASX:OSL) Completes PANCOSIL Study Recruitment
OncoSil Medical (ASX:OSL) completes patient recruitment for the PANCOSIL study, advancing its clinical development of pancreatic cancer treatment.
BCAL Diagnostics Limited (ASX:BDX) Announces Strategic Partnership with Cancer Care Associates
BCAL Diagnostics Limited (ASX:BDX) partners with Cancer Care Associates to accelerate adoption of BREASTEST plus™ in breast cancer diagnostics.
Pro Medicus Limited (ASX:PME) Signs A$170M, 10-Year Contract with UCHealth
Pro Medicus Limited (ASX:PME) signs a A$170M, 10-year contract with UCHealth to implement its Visage 7 imaging platform.
NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) Completes StemSmart Acquisition
NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) completes acquisition of StemSmart technology, appoints new directors, and launches clinical program for Crohn’s disease treatment.
PYC Therapeutics (ASX:PYC) Advances PMS Drug Candidate to Clinical Trials
PYC Therapeutics (ASX:PYC) advances its PMS drug candidate, PYC-002, with promising data supporting its progression to clinical trials.
Percheron Therapeutics (ASX:PER) Secures Worldwide License for HMBD-002
Percheron Therapeutics (ASX:PER) secures exclusive worldwide license for HMBD-002, advancing its oncology drug pipeline and future clinical trials.
Biotron Limited (ASX:BIT) Completes Safety Study for HBV Drug
Biotron Limited (ASX:BIT) completes safety study for its HBV drug, advancing to efficacy testing in animal models.
PYC Therapeutics (ASX:PYC) Aligns with FDA on Registrational Trial Design for RP11 Treatment
PYC Therapeutics (ASX:PYC) aligns with the FDA on registrational trial design for its RP11 treatment, advancing VP-001 to Phase 2/3 studies.